Recombinant Human PILR-alpha Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 6484-PR
Key Product Details
Product Specifications
Source
Gln20-Thr196 with a C-terminal 6-His tag
Purity
Endotoxin Level
N-terminal Sequence Analysis
Thr25 (Minor)
Predicted Molecular Mass
SDS-PAGE
Activity
When recombinant human PANP Fc Chimera is immobilized at 5 μg/mL (100 μL/well), the concentration of Recombinant Human PILR-alpha that produces 50% optimal binding response is approximately 0.4-2 μg/mL.
Formulation, Preparation and Storage
6484-PR
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS and EDTA. |
Reconstitution |
Reconstitute at 100 μg/mL in PBS.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: PILR-alpha
six Ig‑like domains in their extracellular region, PILR-alpha and -beta show only one Ig-like region in their extracellular domain (ECD) (1-5). Human PILR-alpha is a monomeric, 55 kDa, 294 amino acid (aa) type I transmembrane (TM) glycoprotein (3-5). It contains a 178 aa ECD (aa 20-197), a 21 aa TM segment, and a long, 85 aa cytoplasmic region (aa 219-303). The ECD shows one V-type Ig-like domain between aa 32-150, while the cytoplasmic region contains two ITIMs (immunoreceptor Tyr-based inhibitory motifs) between aa 267-272 and 296-301. Given that ITIMs are known to interact with phosphatases such as PTPN6 and PTPN11, the presence of these motifs make mouse PILR-alpha an inhibitory receptor. Three potential isoforms for human PILR-alpha have been reported. The first contains a 24 aa substitution for aa 152‑303, a second possesses a 36 aa substitution for aa 264-303, and a third shows a deletion of aa 152-224 (6). The human PILR-alpha ECD shares 43% aa sequence identity with mouse PILR-alpha ECD, and 82% aa sequence identity with the ECD of human PILR-beta (3, 4).
PILR-alpha is expressed by neutrophils, macrophages, monocytes, mast cells, APCs, microglia, neurons, cardiac muscle and renal proximal plus pancreatic duct eipthelium (4, 7, 8). It has multiple binding partners, including CD99 (4, 9), glycoprotein B/gB of HSV-1 (7), PANP (PILR-associated neural protein) (8) and NPDC1 plus collectin-12 (10). Although PILR-alpha and -beta are related through gene duplication and highly similar in their ECD aa sequence, they do not necessarily share the same ligands (or binding partners), as PILR-beta fails to bind to gB and PANP (8, 10). Notably, PILR-alpha binding appears to be dependent upon the presence of a poorly-defined peptide sequence coupled to a sialylated, O-linked carbohydrate motif (5, 9-12). It is unclear what function(s) can be attributed to PILR-alpha. One possibility suggests that in the early stage of an immune response, PILR-beta predominates over PILR-alpha on the APC surface. Ligation of PILR-beta by CD99 induces IL-12 production and immune cell activation. But this ligation also up‑regulates PILR-alpha expression, and subsequent CD99:PILR‑ alpha engagement now promotes IL-27 production, with a concomitant increase in T cell IL-10 production, and a down‑regulation of the inflammatory response (10).
References
- Wilson, M.D. et al. (2006) Physiol. Genomics 27:201.
- Lanier, L.L. (2001) Curr. Opin. Immunol. 13:326.
- Fournier, N. et al. (2000) J. Immunol. 165:1197.
- Shiratori, I. et al. (2004) J. Exp. Med. 199:525.
- Mousseau, D.D. et al. (2000) J. Biol. Chem. 275:4467.
- SwissProt Accession # Q9UKJ1.
- Tato, C.M. et al. (2012) PLoS ONE 7:e31680.
- Satoh, T. et al. (2008) Cell 132:935.
- Tabata, S. et al. (2008) J. Biol. Chem. 283:8893.
- Sun, Y. et al. (2012) J. Biol. Chem. 287:15837.
- Wang, J. et al. (2008) J. Biol. Chem. 180:1686.
- Arii, J. et al. (2010) J. Virol. 84:10733.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional PILR-alpha Products
Product Documents for Recombinant Human PILR-alpha Protein, CF
Product Specific Notices for Recombinant Human PILR-alpha Protein, CF
For research use only